{
    "Trade/Device Name(s)": [
        "Afinion HbA1c Dx on Afinion 2",
        "Afinion HbA1c Dx"
    ],
    "Submitter Information": "Alere Technologies AS",
    "510(k) Number": "K182988",
    "Predicate Device Reference 510(k) Number(s)": [
        "K180296",
        "K050574",
        "K072409",
        "K110056",
        "K151809",
        "K171650"
    ],
    "Regulatory Class": "Class II",
    "Product Code(s)": [
        "PDJ",
        "JQT"
    ],
    "Summary Letter Date": "October 26, 2018",
    "Summary Letter Received Date": "October 29, 2018",
    "Submission Date": "November 28, 2018",
    "Regulation Number(s)": [
        "21 CFR 862.1373",
        "21 CFR 862.2400"
    ],
    "Regulation Name(s)": [
        "Hemoglobin A1c test system"
    ],
    "Analyte Class(es)": [
        "chemistry",
        "hematology"
    ],
    "Analyte(s)": [
        "Hemoglobin A1c"
    ],
    "Specimen Type(s)": [
        "Whole Blood",
        "Venous Whole Blood",
        "Capillary Whole Blood"
    ],
    "Specimen Container(s)": [],
    "Instrument(s)/Platform(s)": [
        "Afinion 2 Analyzer"
    ],
    "Method(s)/Technology(ies)": [
        "Boronate affinity assay",
        "Automated point-of-care testing"
    ],
    "Methodologies": [],
    "Submission Type(s)": [
        "Assay",
        "Analyzer",
        "Test Cartridges"
    ],
    "Document Summary": "FDA 510(k) summary for Afinion HbA1c Dx assay on Afinion 2 Analyzer for quantitative measurement of HbA1c in whole blood as an aid in diabetes diagnosis and monitoring",
    "Indications for Use Summary": "In vitro diagnostic test for quantitative determination of glycated hemoglobin (HbA1c) in human venous and capillary whole blood, used as an aid in diagnosis of diabetes and in identifying patients at risk for developing diabetes",
    "fda_folder": "Clinical Chemistry"
}